BeyondSpring Inc.

Stocks

BYSI

KYG108301006

Market Closed - Nasdaq 20:00:00 29/10/2026 GMT			5-day change	1st Jan Change
0.5167 ^USD	-1.49%		+16.09%	-68.30%

10-13	BeyondSpring Inc. - Shareholder/Analyst Call
09-29	BeyondSpring Inc. Announces FDA Fast Track Designation For Plinabulin And Docetaxel In Post-ICI Non-Squamous NSCLC	CI

Transcript : BeyondSpring Inc. - Shareholder/Analyst Call

Published on 10/13/2026 at 02:50 pm BST - Modified on 10/13/2026 at 03:05 pm BST

S&P Capital IQ

Presenter Speech
Unknown Attendee (Attendees)

Good morning, and welcome to the 2026 Annual Meeting of Shareholders of BeyondSpring Inc.

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about BeyondSpring Inc.

10-13	BeyondSpring Inc. - Shareholder/Analyst Call
09-29	BeyondSpring Inc. Announces FDA Fast Track Designation For Plinabulin And Docetaxel In Post-ICI Non-Squamous NSCLC	CI
09-29	BeyondSpring Inc. - Special Call
08-14	BeyondSpring Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06-29	BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell 3000E Growth Benchmark	CI
06-28	BeyondSpring Inc.(NasdaqCM:BYSI) dropped from Russell Microcap Growth Benchmark Index	CI
06-04	BeyondSpring Inc. Announces Chief Executive Officer Changes, Effective July 1, 2026	CI
06-04	BeyondSpring Inc. Announces Appointment of Na Li as Chief Financial Officer, Effective July 1, 2026	CI
06-04	BeyondSpring Inc. Appoints Dr. Jiangwen Majeti as Vice Chairman, Effective July 1, 2026	CI
06-02	BeyondSpring Presents Latest Update Of Phase 2 Study Demonstrating Durable Clinical Benefit Of Pembrolizumab Plus Plinabulin And Docetaxel In Metastatic NSCLC After Progression On First-Line Immune Checkpoint Inhibitor Therapy	CI
05-13	BeyondSpring Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	BeyondSpring Inc Reports Compelling New Data on Plinabulin Advances Both the Anticancer Efficacy and Safety of Adc Drugs	CI
03-25	BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-12	BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3	CI
12-11	Beyondspring Inc. Announces New Post-Hoc Analyses from Its Global Phase 3 Dublin-3Study	CI

Chart BeyondSpring Inc.

Duration

Period

BYSI: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

Projected Income Statement - Annual - BeyondSpring Inc.

More financial data